Literature DB >> 11756980

Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis.

Anna Wald1, Katherine Link.   

Abstract

To determine the contribution of herpes simplex type 2 (HSV-2) infection to the risk of human immunodeficiency virus (HIV) acquisition, a systematic review of literature and data synthesis were done. Thirty-one studies addressed the risk of HIV infection in HSV-2-seropositive persons. For 9 cohort and nested case-control studies that documented HSV-2 infection before HIV acquisition, the risk estimate was 2.1 (95% confidence interval, 1.4-3.2). Thus, the attributable risk percentage of HIV to HSV-2 was 52%, and the population attributable risk percentage was 19% in populations with 22% HSV-2 prevalence but increased to 47% in populations with 80% HSV-2 prevalence. For 22 case-control and cross-sectional studies, the risk estimate was 3.9 (95% confidence interval, 3.1-5.1), but the temporal sequence of the 2 infections cannot be documented. Control strategies for HSV-2 need to be incorporated into control of sexually transmitted infections as a strategy for HIV prevention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11756980     DOI: 10.1086/338231

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  249 in total

1.  Plasma versus serum for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies with a glycoprotein G2-based enzyme immunoassay.

Authors:  Thomas L Cherpes; Leslie A Meyn; Sharon L Hillier
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

2.  Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation.

Authors:  Catia T Perciani; Bashir Farah; Rupert Kaul; Mario A Ostrowski; Salaheddin M Mahmud; Omu Anzala; Walter Jaoko; Kelly S MacDonald
Journal:  J Clin Invest       Date:  2019-01-22       Impact factor: 14.808

Review 3.  Immune modulation during latent herpesvirus infection.

Authors:  Douglas W White; R Suzanne Beard; Erik S Barton
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

4.  Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.

Authors:  Christopher S Morello; Michael S Levinson; Kimberly A Kraynyak; Deborah H Spector
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

5.  Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor.

Authors:  David M Koelle; Zhi Liu; Christopher L McClurkan; Randal C Cevallos; Jeffrey Vieira; Nancy A Hosken; Clement A Meseda; Devon C Snow; Anna Wald; Lawrence Corey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

Review 6.  Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges.

Authors:  P Mayaud; D Mabey
Journal:  Sex Transm Infect       Date:  2004-06       Impact factor: 3.519

7.  Preventing sexually transmitted infections: back to basics.

Authors:  Anne Rompalo
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

8.  Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.

Authors:  Sita Awasthi; John W Balliet; Jessica A Flynn; John M Lubinski; Carolyn E Shaw; Daniel J DiStefano; Michael Cai; Martha Brown; Judith F Smith; Rose Kowalski; Ryan Swoyer; Jennifer Galli; Victoria Copeland; Sandra Rios; Robert C Davidson; Maya Salnikova; Susan Kingsley; Janine Bryan; Danilo R Casimiro; Harvey M Friedman
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

9.  Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey.

Authors:  A L Cunningham; R Taylor; J Taylor; C Marks; J Shaw; A Mindel
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

10.  Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Authors:  Ana M Chamoun-Emanuelli; Michael Bobardt; Bernard Moncla; Marie K Mankowski; Roger G Ptak; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.